SWOG clinical trial number
SWOG-9339
Evaluation of Topotecan in Esophageal Carcinoma, Phase II
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Evaluation of Topotecan in Esophageal Carcinoma, Phase II
Activated
03/01/1994
Closed
12/15/1995
Research committees
Gastrointestinal Cancer
Publication Information Expand/Collapse
2000
A phase II trial of topotecan in esophageal carcinoma: A Southwest Oncology Group study (SWOG-9339)
Other Clinical Trials
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
85%
Open
Phase